Starmer's US pharma deal criticized as costly threat to NHS funding and public health
By
Aditya Chakrabortty
Summary
Aditya Chakrabortty argues that Keir Starmer's government has pushed through a law enabling a US pharma deal that will harm the NHS by costing billions, diverting funds from doctors, nurses, and cancer care. The piece frames this as a profound democratic failure where elected officials are acting against public interests rather than serving them.
Source
bskyStarmer's US pharma deal criticized as costly threat to NHS funding and public healththeguardian.comKey quotes
· 3 pulledThe entire political system rests on one basic premise: they work for us.
Rather than working for us, Keir Starmer and his ministers are acting against us.
They have rammed through parliament a sweeping law that will, independent experts agree, harm the public.
You might also wanna read
Activists oppose NHS England's use of Palantir software for health records
The article is a strongly opinionated piece opposing NHS England's decision to roll out Palantir's software for managing health records. It
notopalantir.goodlawproject.org·17d agoActivists oppose NHS England's use of Palantir software for health records
The article is a strongly opinionated piece opposing NHS England's decision to roll out Palantir's software for managing health records. It
notopalantir.goodlawproject.org·17d agoThreat in Your Medicine Cabinet: The FDA's Gamble on America's Drugs
U.S. restrictions on Chinese biotech could harm patients, argues editorial
The article argues against U.S. efforts to restrict collaboration with China's biotechnology industry, framing it as an extension of the tec
economist.com·12d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.